SCHEMBL775763

SCHEMBL775763

Cc1ccc(C(=O)CS(=O)(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.61
RECQL P46063 1/20 0.56
GSK3B P49841 1/20 0.55
LMNA P02545 2/20 0.54
ALDH1A1 P00352 5/20 0.53
PKM P14618 2/20 0.53
KMT2A Q03164 5/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
MEN1 O00255 1/20 0.52
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
PAX8 Q06710 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11910519 0.83 HSD11B1 (0.61) HSD11B1RECQLGSK3BLMNAALDH1A1
SCHEMBL28701120 0.81 NPC1 (0.54) RECQLLMNAALDH1A1PKMNPC1
SCHEMBL3027222 0.80 HSD11B1 (0.57) HSD11B1RECQLGSK3BLMNAALDH1A1
SCHEMBL29012562 0.80 HSD11B1 (0.83) HSD11B1RECQLLMNAALDH1A1PKM
SCHEMBL778194 0.80 KMT2A (0.59) HSD11B1RECQLGSK3BLMNAALDH1A1
SCHEMBL3496147 0.79 LMNA (0.46) HSD11B1RECQLLMNAALDH1A1PKM
SCHEMBL137832 0.78 MAPK1 (0.56) HSD11B1RECQLGSK3BLMNAALDH1A1
SCHEMBL777531 0.77 PARP1 (0.52) RECQLLMNAKMT2AMEN1MAPT
SCHEMBL7868384 0.77 MAPK1 (0.54) HSD11B1RECQLGSK3BLMNAALDH1A1
SCHEMBL6202982 0.76 HSD11B1 (1.00) HSD11B1RECQLLMNAALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11535647-B2 Peptide purification method using sulfonate compound NAGASE & CO., LTD. (JP) 2022-12-27 US disclosed
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND NAGASE & CO., LTD. (JP) 2022-05-12 US disclosed
EP-3851446-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND Nagase & Co., Ltd. (JP) 2021-07-21 EP disclosed
WO-2020054287-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND 長瀬産業株式会社 2020-03-19 WO disclosed
US-9343777-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2016-05-17 US disclosed
US-9252457-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2016-02-02 US disclosed
US-20120177988-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-07-12 US disclosed
US-20120070731-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND VIP, IAPP, RPS27A HSD11B1 2292/4885RECQL 4853/4885GSK3B 4874/4885
US-11535647-B2 Peptide purification method using sulfonate compound VIP, IAPP, RPS27A HSD11B1 2292/4885RECQL 4853/4885GSK3B 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.